Search

News European Survey on Prophylactic Treatment of Chemotherapy-Induced Nausea and Vomiting Suggests Gaps in Practice and Ways to Improve

Using recommended guidelines for antiemetic prophylaxis can prevent chemotherapy-induced nausea and vomiting (CINV). Nurses play a significant role in administering prophylactic treatment for CINV. Therefore, a survey was conducted in 16 European countries among middle medical personnel to evaluate the use of recommended antiemetic prophylaxis in oncology practice and the obstacles to its administration.

Source: Antiemetic Therapy 13. 3. 2020

News Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia

Experience shows that monitoring joint changes, especially subclinical ones, is very necessary in the care of hemophiliacs. Unfortunately, conventional X-rays cannot detect early changes in joints. Magnetic resonance imaging (MRI) plays an indispensable role in detecting these changes.

Source: Hemophilia 16. 3. 2020

News Type of Pharmacological Thromboprophylaxis and Disease Stage as Risk Factors for Bleeding in Patients After Colorectal Cancer Surgery

Japanese authors of a study published last year in the World Journal of Surgical Oncology attempted to answer the question of whether the incidence of postoperative bleeding in patients undergoing elective surgery for colorectal cancer is associated with the type of pharmacological prophylaxis or the disease stage.

Source: Thromboprophylaxis 14. 3. 2020

News Direct Comparison of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis

The final results of the direct comparison of ixekizumab and adalimumab in the therapy of biologic-naïve patients with psoriatic arthritis were presented at the annual conference of the American College of Rheumatology (ACR/ARP) in November 2019 in Atlanta.

Source: Biological Treatment 6. 4. 2020

News Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection

Italian authors published the results of a meta-analysis of studies at the end of March, assessing the prevalence of diabetes among individuals infected with SARS-CoV2 and the impact of diabetes on the severity and progression of the infection.

Source: Modern Treatment of Diabetes 14. 4. 2020

News Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis

Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the Czech Republic for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. Its efficacy compared to adalimumab in PsA was evaluated in the head-to-head SPIRIT-H2H study. A post-hoc analysis of this study focusing on a subpopulation of patients with PsA and concurrent moderate to severe plaque psoriasis was presented at the Congress of the European Academy of Dermatology and Venereology (EADV) in October 2019 in Madrid.

Source: Biological Treatment 9. 5. 2020

News Comparison of the Efficacy and Safety of Two Enoxaparin Dosing Regimens in Patients After Chest Surgery

Effective prevention of thromboembolic disease in patients undergoing chest surgery is one of the key therapeutic goals. However, the question remains as to what dose of low molecular weight heparin is optimal for these individuals. A multicenter clinical trial compared the efficacy of a fixed dose of enoxaparin to a weight-adjusted dose.

Source: Thromboprophylaxis 31. 8. 2020

News Empagliflozin in the Treatment of Patients with Chronic Heart Failure

Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.

Source: Heart Failure 7. 12. 2021

News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC

Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.

Source: Genetic Profile and Treatment of NSCLC 23. 7. 2021

News Perioperative substitution therapy in patients with vWD must be tailored

Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.

Source: Von Willebrand Disease 25. 8. 2021

News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease

A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).

Source: Von Willebrand Disease 25. 8. 2021

News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?

Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.

Source: Sartans in the Treatment of Hypertension 19. 4. 2021

News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?

The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.

Source: Anticoagulant Treatment 29. 3. 2021

News Sport as an Important Part of the Life of Hemophiliacs

People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.

Source: Hemophilia with Movement 7. 4. 2021

News Diabetic Nephropathy and COVID-19: Fatal Connection?

People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus –⁠ angiotensin-converting enzyme 2 (ACE2).

Source: Diabetes 26. 4. 2021